Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03116685
Other study ID # OC5-DB-02
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 9, 2018
Est. completion date April 15, 2021

Study information

Verified date October 2021
Source OxThera
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of OC5 in patients with PH.


Description:

To evaluate the efficacy of Oxabact following 52 weeks treatment in subjects with maintained kidney function, but below the lower limit of the normal range (estimated glomerular filtration rate [eGFR] < 90 ml/min/1.73 m2) and a total plasma oxalate (Pox) concentration ≥ 10 μmol/L. Parameters to be evaluated include the ability to stabilise/reduce Pox concentration, to stabilise/improve kidney function and to reduce oxalate deposits in primary hyperoxaluria (PH) subjects.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date April 15, 2021
Est. primary completion date April 15, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: 1. Signed informed consent (as applicable for the age of the subject) 2. A diagnosis of PH (as determined by standard diagnostic methods). 3. eGFR < 90 ml/min/1.73 m2. The Schwartz formula will be used to estimate GFR for children (age below 18), and CKD-EPI formula will be used for adults (age 18 or above). 4. Plasma oxalate concentration =10 µmol/L in total plasma oxalate. 5. Male or female patients = 2 years of age. 6. Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must not change the dose during the study. Patients not receiving vitamin B6 at study entry must be willing to refrain from initiating pyridoxine during study participation. Exclusion Criteria: 1. Inability to swallow size 4 capsules. 2. Subjects that have undergone transplantation (solid organ or bone marrow). 3. Patients requiring dialysis or at immediate risk for kidney failure or expected to be in need of dialysis during the study period. 4. The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome. 5. Use of antibiotics to which O. formigenes is sensitive. (This includes current antibiotic use, or antibiotics use within 14 days of initiating study medication). 6. Current treatment with a separate ascorbic acid preparation. 7. Pregnant women (or women who are planning to become pregnant) or lactating women. 8. Women of childbearing potential who are not using adequate contraceptive precautions. Please see section 7.3 regarding requirements for contraception. 9. Presence of a medical condition that the Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures or any condition that is likely to interfere with the study drug mechanism of action (such as abnormal GI function). 10. Participation in any interventional study of another investigational product, biologic, device, or other agent within 60 days prior to the first dose of OC5 or not willing to forego other forms of investigational treatment during this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Oxabact OC5 - Oxalobacter formigenes HC-1
Active study drug
Other:
Placebo
Placebo

Locations

Country Name City State
Belgium Centre Hospitalier Universitaire de Liège Liège
France Hôpital Robert Debré Paris
Germany Kindernierenzentrum Bonn Bonn
Spain Hospital Vall d' Hebron Barcelona
Tunisia Hédi Chaker University Hospital Sfax
Tunisia Sahloul University Hospital Sousse
Tunisia Charles Nicolle University Hospital Tunis
United Kingdom Royal Free Hospital London
United Kingdom Nottingham Children's Hospital Nottingham
United States Vanderbilt University Hospital Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
OxThera

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  Spain,  Tunisia,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Plasma Oxalate Concentration After 52 Weeks of Treatment Change from baseline in total plasma oxalate concentration after 52 weeks of treatment in micromole/liter 52 weeks
Secondary Change From Baseline in Kidney Function Evaluation based on eGFR calculation using the 2009 creatinine-based "Schwartz bedside" equation (for children below 18 years of age) (Schwartz et al., 2009) and 2009 creatinine-based CKD-EPI equation for adults (Levey et al., 2009). Subjects who turn 18 during the study period were continuously evaluated using the Schwartz equation, ie the equation used at baseline was kept throughout the study. 52 weeks
Secondary Frequency of Kidney Stone Events Number of kidney stone events for each patient Through week 48
See also
  Status Clinical Trial Phase
Withdrawn NCT00875823 - International Registry for Primary Hyperoxaluria N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02340689 - Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Completed NCT00638703 - Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients Phase 2/Phase 3
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT03819647 - Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria Phase 2
Recruiting NCT02026388 - Rare Kidney Stone Consortium Biobank
Completed NCT02000219 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis Phase 2
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Recruiting NCT00588562 - Rare Kidney Stone Consortium Patient Registry
Completed NCT03391804 - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia Phase 2
Recruiting NCT05107830 - Phenotyping of Primary Hyperoxaluria
Active, not recruiting NCT04152200 - A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 Phase 3
Recruiting NCT05001269 - Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function Phase 2
Completed NCT03392896 - Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria Phase 1
Completed NCT02012985 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria Phase 1/Phase 2
Completed NCT01037231 - Phase 2/3 Oxabact Study Phase 2/Phase 3
Completed NCT00589225 - Primary Hyperoxaluria Mutation Genotyping Phase 1
Completed NCT02124395 - Health-related Quality of Life in Rare Kidney Stone
Completed NCT03350451 - An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 Phase 2